Alleviation of Common Cold Symptoms
Public ClinicalTrials.gov record NCT06106880. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Alleviation of Upper Respiratory Inflammation and Associated Common Cold Symptoms
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Upper respiratory infections (URIs) have long posed a significant burden to the US healthcare system. Well before the coronavirus disease of 2019 (COVID-19) pandemic they have been among the most common acute outpatient illnesses, causing 75-100 million physician visits each year on average, and costing the health care system billions of dollars annually. This double-blind randomized placebo-controlled study tested the efficacy of two anti-inflammatory throat sprays against placebo and against a throat spray taken in conjunction with 325mg of aspirin, a well-known systemically administered cyclooxygenase (COX) inhibitor. Participants having common cold symptoms lasting less than two days were enrolled and given treatment to administer at home. Various common cold symptoms were assessed and measured via clinically validated self-assessment scales. Participants were screened for influenza and COVID-19 before enrollment and were excluded if found positive.
Study identification
- NCT ID
- NCT06106880
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 157 participants
Conditions and interventions
Conditions
Interventions
- Wintergreen Throat Spray and Aspirin Tablet Drug
- Aspirin Throat Spray and Placebo Tablet Drug
- Wintergreen Throat Spray and Placebo Tablet Dietary Supplement
- Placebo Throat Spray and Placebo Tablet Other
Drug · Dietary Supplement · Other
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 25, 2022 (Actual)
- Primary completion
- Apr 8, 2023 (Actual)
- Completion
- Jun 16, 2023 (Actual)
- Last update posted
- Jan 16, 2024
2022 – 2023
United States locations
- U.S. sites
- 6
- U.S. states
- 6
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Telemedicine and Home Visit | Irvine | California | 92614-0120 | — |
| Telemedicine and Home Visit | Washington D.C. | District of Columbia | 20016 | — |
| Telemedicine and Home Visit | Atlanta | Georgia | 30002-0082 | — |
| Telemedicine and Home Visit | Baltimore | Maryland | 21215 | — |
| Telemedicine and Home Visit | New York | New York | 11385 | — |
| Telemedicine and Home Visit | Houston | Texas | 77054-3036 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06106880, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 16, 2024 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06106880 live on ClinicalTrials.gov.